182 related articles for article (PubMed ID: 31882679)
1. Inducing Tumor Suppressive Microenvironments through Genome Edited CD47
Jayaraman Rukmini S; Bi H; Sen P; Everhart B; Jin S; Ye K
Sci Rep; 2019 Dec; 9(1):20057. PubMed ID: 31882679
[TBL] [Abstract][Full Text] [Related]
2. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
3. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein.
Zheng Y; Zou F; Wang J; Yin G; Le V; Fei Z; Liu J
J Biol Chem; 2015 Apr; 290(14):8975-86. PubMed ID: 25697354
[TBL] [Abstract][Full Text] [Related]
5. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.
Nath PR; Pal-Nath D; Mandal A; Cam MC; Schwartz AL; Roberts DD
Cancer Immunol Res; 2019 Sep; 7(9):1547-1561. PubMed ID: 31362997
[TBL] [Abstract][Full Text] [Related]
7. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
8. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.
Stirling ER; Terabe M; Wilson AS; Kooshki M; Yamaleyeva LM; Alexander-Miller MA; Zhang W; Miller LD; Triozzi PL; Soto-Pantoja DR
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36418073
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
[TBL] [Abstract][Full Text] [Related]
10. Nitrated T cell epitope linked vaccine targeting CD47 elicits antitumor immune responses and acts synergistically with vaccine targeting PDL1.
Deng D; Li G; Xia X; Xu S; Gao L; Zhang L; Yao W; Tian H; Gao X
Int Immunopharmacol; 2024 Feb; 128():111374. PubMed ID: 38181672
[TBL] [Abstract][Full Text] [Related]
11. Localized CD47 blockade enhances immunotherapy for murine melanoma.
Ingram JR; Blomberg OS; Sockolosky JT; Ali L; Schmidt FI; Pishesha N; Espinosa C; Dougan SK; Garcia KC; Ploegh HL; Dougan M
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10184-10189. PubMed ID: 28874561
[TBL] [Abstract][Full Text] [Related]
12. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
[TBL] [Abstract][Full Text] [Related]
13. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
14. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.
Hutter G; Theruvath J; Graef CM; Zhang M; Schoen MK; Manz EM; Bennett ML; Olson A; Azad TD; Sinha R; Chan C; Assad Kahn S; Gholamin S; Wilson C; Grant G; He J; Weissman IL; Mitra SS; Cheshier SH
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):997-1006. PubMed ID: 30602457
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.
Li Y; Zhang M; Wang X; Liu W; Wang H; Yang YG
Nat Commun; 2020 Jan; 11(1):581. PubMed ID: 31996683
[TBL] [Abstract][Full Text] [Related]
16. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
17. CD47 Blockade and Cowpea Mosaic Virus Nanoparticle In Situ Vaccination Triggers Phagocytosis and Tumor Killing.
Wang C; Steinmetz NF
Adv Healthc Mater; 2019 Apr; 8(8):e1801288. PubMed ID: 30838815
[TBL] [Abstract][Full Text] [Related]
18. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
19. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
Wang Y; Ni H; Zhou S; He K; Gao Y; Wu W; Wu M; Wu Z; Qiu X; Zhou Y; Chen B; Pan D; Huang C; Li M; Bian Y; Yang M; Miao L; Liu J
Cancer Immunol Immunother; 2021 Feb; 70(2):365-376. PubMed ID: 32761423
[TBL] [Abstract][Full Text] [Related]
20. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
